|
1
|
Jemal A, Bray F, Center MM, Ferlay J, Ward
E and Forman D: Global cancer statistics. CA Cancer J Clin.
61:69–90. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Panzarella V, Pizzo G, Calvino F,
Compilato D, Colella G and Campisi G: Diagnostic delay in oral
squamous cell carcinoma: The role of cognitive and psychological
variables. Int J Oral Sci. 6:39–45. 2014. View Article : Google Scholar :
|
|
3
|
Choi S and Myers JN: Molecular
pathogenesis of oral squamous cell carcinoma: Implications for
therapy. J Dent Res. 87:14–32. 2008. View Article : Google Scholar
|
|
4
|
Ratajczak-Wrona W, Jablonska E, Antonowicz
B, Dziemianczyk D and Grabowska SZ: Levels of biological markers of
nitric oxide in serum of patients with squamous cell carcinoma of
the oral cavity. Int J Oral Sci. 5:141–145. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Principe S, Hui AB, Bruce J, Sinha A, Liu
FF and Kislinger T: Tumor-derived exosomes and microvesicles in
head and neck cancer: Implications for tumor biology and biomarker
discovery. Proteomics. 13:1608–1623. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Li X, Amazit L, Long W, Lonard DM, Monaco
JJ and O'Malley BW: Ubiquitin- and ATP-independent proteolytic
turnover of p21 by the REGgamma-proteasome pathway. Mol Cell.
26:831–842. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Hu L, Lu F, Wang Y, Liu Y, Liu D, Jiang Z,
Wan C, Zhu B, Gan L, Wang Y, et al: RACK1, a novel
hPER1-interacting protein. J Mol Neurosci. 29:55–63. 2006.
View Article : Google Scholar
|
|
8
|
Besson A, Wilson TL and Yong VW: The
anchoring protein RACK1 links protein kinase Cepsilon to integrin
beta chains. Requirements for adhesion and motility. J Biol Chem.
277:22073–22084. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Daniels CC, Rovnak J and Quackenbush SL:
Walleye dermal sarcoma virus Orf B functions through receptor for
activated C kinase (RACK1) and protein kinase C. Virology.
375:550–560. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Wehner P, Shnitsar I, Urlaub H and
Borchers A: RACK1 is a novel interaction partner of PTK7 that is
required for neural tube closure. Development. 138:1321–1327. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Li J, Guo Y, Feng X, Wang Z, Wang Y, Deng
P, Zhang D, Wang R, Xie L, Xu X, et al: Receptor for activated C
kinase 1 (RACK1): A regulator for migration and invasion in oral
squamous cell carcinoma cells. J Cancer Res Clin Oncol.
138:563–571. 2012. View Article : Google Scholar
|
|
12
|
Berns H, Humar R, Hengerer B, Kiefer FN
and Battegay EJ: RACK1 is up-regulated in angiogenesis and human
carcinomas. FASEB J. 14:2549–2558. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Li JJ and Xie D: RACK1, a versatile hub in
cancer. Oncogene. 34:1890–1898. 2015. View Article : Google Scholar
|
|
14
|
Link AJ, Eng J, Schieltz DM, Carmack E,
Mize GJ, Morris DR, Garvik BM and Yates JR III: Direct analysis of
protein complexes using mass spectrometry. Nat Biotechnol.
17:676–682. 1999. View
Article : Google Scholar : PubMed/NCBI
|
|
15
|
Ruan Y, Sun L, Hao Y, Wang L, Xu J, Zhang
W, Xie J, Guo L, Zhou L, Yun X, et al: Ribosomal RACK1 promotes
chemoresistance and growth in human hepatocellular carcinoma. J
Clin Invest. 122:2554–2566. 2012. View
Article : Google Scholar : PubMed/NCBI
|
|
16
|
Shi S, Deng YZ, Zhao JS, Ji XD, Shi J,
Feng YX, Li G, Li JJ, Zhu D, Koeffler HP, et al: RACK1 promotes
non-small-cell lung cancer tumorigenicity through activating sonic
hedgehog signaling pathway. J Biol Chem. 287:7845–7858. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Wu J, Meng J, Du Y, Huang Y, Jin Y, Zhang
J, Wang B, Zhang Y, Sun M and Tang J: RACK1 promotes the
proliferation, migration and invasion capacity of mouse
hepatocellular carcinoma cell line in vitro probably by PI3K/Rac1
signaling pathway. Biomed Pharmacother. 67:313–319. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Deng YZ, Yao F, Li JJ, Mao ZF, Hu PT, Long
LY, Li G, Ji XD, Shi S, Guan DX, et al: RACK1 suppresses gastric
tumorigenesis by stabilizing the β-catenin destruction complex.
Gastroenterology. 142:812–823.e15. 2012. View Article : Google Scholar
|
|
19
|
Li Y, Peart MJ and Prives C: Stxbp4
regulates DeltaNp63 stability by suppression of RACK1-dependent
degradation. Mol Cell Biol. 29:3953–3963. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Sutton P, Borgia JA, Bonomi P and Plate
JM: Lyn, a Src family kinase, regulates activation of epidermal
growth factor receptors in lung adenocarcinoma cells. Mol Cancer.
12:762013. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Zhang D, Wang Q, Zhu T, Cao J, Zhang X,
Wang J, Wang X, Li Y, Shen B and Zhang J: RACK1 promotes the
proliferation of THP1 acute myeloid leukemia cells. Mol Cell
Biochem. 384:197–202. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Harada H, Quearry B, Ruiz-Vela A and
Korsmeyer SJ: Survival factor-induced extracellular
signal-regulated kinase phosphorylates BIM, inhibiting its
association with BAX and proapoptotic activity. Proc Natl Acad Sci
USA. 101:15313–15317. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Zhang W, Cheng GZ, Gong J, Hermanto U,
Zong CS, Chan J, Cheng JQ and Wang LH: RACK1 and CIS mediate the
degradation of BimEL in cancer cells. J Biol Chem. 283:16416–16426.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Subauste MC, Ventura-Holman T, Du L,
Subauste JS, Chan SL, Yu VC and Maher JF: RACK1 downregulates
levels of the pro-apoptotic protein Fem1b in apoptosis-resistant
colon cancer cells. Cancer Biol Ther. 8:2297–2305. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Sang N, Severino A, Russo P, Baldi A,
Giordano A, Mileo AM, Paggi MG and De Luca A: RACK1 interacts with
E1A and rescues E1A-induced yeast growth inhibition and mammalian
cell apoptosis. J Biol Chem. 276:27026–27033. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Mamidipudi V and Cartwright CA: A novel
pro-apoptotic function of RACK1: Suppression of Src activity in the
intrinsic and Akt pathways. Oncogene. 28:4421–4433. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Nagashio R, Sato Y, Matsumoto T, Kageyama
T, Satoh Y, Shinichiro R, Masuda N, Goshima N, Jiang SX and Okayasu
I: Expression of RACK1 is a novel biomarker in pulmonary
adeno-carcinomas. Lung Cancer. 69:54–59. 2010. View Article : Google Scholar
|
|
28
|
Zhong X, Li M, Nie B, Wu F, Zhang L, Wang
E and Han Y: Overexpressions of RACK1 and CD147 associated with
poor prognosis in stage T1 pulmonary adenocarcinoma. Ann Surg
Oncol. 20:1044–1052. 2013. View Article : Google Scholar
|
|
29
|
Hu F, Tao Z, Wang M, Li G, Zhang Y, Zhong
H, Xiao H, Xie X and Ju M: RACK1 promoted the growth and migration
of the cancer cells in the progression of esophageal squamous cell
carcinoma. Tumour Biol. 34:3893–3899. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Wang Z, Jiang L, Huang C, Li Z, Chen L,
Gou L, Chen P, Tong A, Tang M, Gao F, et al: Comparative proteomics
approach to screening of potential diagnostic and therapeutic
targets for oral squamous cell carcinoma. Mol Cell Proteomics.
7:1639–1650. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Wang Z, Zhang B, Jiang L, Zeng X, Chen Y,
Feng X, Guo Y and Chen Q: RACK1, an excellent predictor for poor
clinical outcome in oral squamous carcinoma, similar to Ki67. Eur J
Cancer. 45:490–496. 2009. View Article : Google Scholar
|
|
32
|
Zhou Y, Zhu X, Lu R, Dan H, Wang F, Wang
J, Li J, Feng X, Wang H, Ji N, et al: Vesicular stomatitis virus
matrix protein (VSVMP) inhibits the cell growth and tumor
angiogenesis in oral squamous cell carcinoma. Oral Oncol.
48:110–116. 2012. View Article : Google Scholar
|
|
33
|
Jiang L, Zeng X, Wang Z, Ji N, Zhou Y, Liu
X and Chen Q: Oral cancer overexpressed 1 (ORAOV1) regulates cell
cycle and apoptosis in cervical cancer HeLa cells. Mol Cancer.
9:202010. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Li J, Feng X, Sun C, Zeng X, Xie L, Xu H,
Li T, Wang R, Xu X, Zhou X, et al: Associations between proteasomal
activator PA28γ and outcome of oral squamous cell carcinoma:
Evidence from cohort studies and functional analyses. EBio Med.
2:849–856. 2015.
|
|
35
|
Li Y, Wang J, Wang F, Wang H, Wang J, Zeng
X, Liao G, Dan H and Chen Q: Tissue microarray analysis reveals the
expression and prognostic significance of phosphorylated
AktThr308 in oral squamous cell carcinoma. Oral Surg
Oral Med Oral Pathol Oral Radiol. 116:591–597. 2013. View Article : Google Scholar
|
|
36
|
Wang Y, Lin L, Xu H, Li T, Zhou Y, Dan H,
Jiang L, Liao G, Zhou M, Li L, et al: Genetic variants in AKT1 gene
were associated with risk and survival of OSCC in Chinese Han
population. J Oral Pathol Med. 44:45–50. 2015. View Article : Google Scholar
|
|
37
|
Peng R, Jiang B, Ma J, Ma Z, Wan X, Liu H,
Chen Z, Cheng Q and Chen R: Forced downregulation of RACK1 inhibits
glioma development by suppressing Src/Akt signaling activity. Oncol
Rep. 30:2195–2202. 2013.PubMed/NCBI
|
|
38
|
Kapoor V, Zaharieva MM, Das SN and Berger
MR: Erufosine simultaneously induces apoptosis and autophagy by
modulating the Akt-mTOR signaling pathway in oral squamous cell
carcinoma. Cancer Lett. 319:39–48. 2012. View Article : Google Scholar
|
|
39
|
Patel V, Marsh CA, Dorsam RT, Mikelis CM,
Masedunskas A, Amornphimoltham P, Nathan CA, Singh B, Weigert R,
Molinolo AA, et al: Decreased lymphangiogenesis and lymph node
metastasis by mTOR inhibition in head and neck cancer. Cancer Res.
71:7103–7112. 2011. View Article : Google Scholar
|
|
40
|
Wang Z, Martin D, Molinolo AA, Patel V,
Iglesias-Bartolome R, Degese MS, Vitale-Cross L, Chen Q and Gutkind
JS: mTOR co-targeting in cetuximab resistance in head and neck
cancers harboring PIK3CA and RAS mutations. J Natl Cancer Inst.
106:1062014. View Article : Google Scholar
|
|
41
|
Thomas SM and Grandis JR: The current
state of head and neck cancer gene therapy. Hum Gene Ther.
20:1565–1575. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Liu S, Xu X, Zeng X, Li L, Chen Q and Li
J: Tumor-targeting bacterial therapy: A potential treatment for
oral cancer (Review). Oncol Lett. 8:2359–2366. 2014.PubMed/NCBI
|
|
43
|
Li Y, Li LJ, Zhang ST, Wang LJ, Zhang Z,
Gao N, Zhang YY and Chen QM: In vitro and clinical studies of gene
therapy with recombinant human adenovirus-p53 injection for oral
leukoplakia. Clin Cancer Res. 15:6724–6731. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Zhang S, Li Y, Li L, Zhang Y, Gao N, Zhang
Z and Zhao H: Phase I study of repeated intraepithelial delivery of
adenoviral p53 in patients with dysplastic oral leukoplakia. J Oral
Maxillofac Surg. 67:1074–1082. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Emamian ES, Hall D, Birnbaum MJ,
Karayiorgou M and Gogos JA: Convergent evidence for impaired
AKT1-GSK3beta signaling in schizophrenia. Nat Genet. 36:131–137.
2004. View
Article : Google Scholar : PubMed/NCBI
|
|
46
|
George S, Rochford JJ, Wolfrum C, Gray SL,
Schinner S, Wilson JC, Soos MA, Murgatroyd PR, Williams RM, Acerini
CL, et al: A family with severe insulin resistance and diabetes due
to a mutation in AKT2. Science. 304:1325–1328. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Altomare DA and Testa JR: Perturbations of
the AKT signaling pathway in human cancer. Oncogene. 24:7455–7464.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Franke TF: PI3K/Akt: Getting it right
matters. Oncogene. 27:6473–6488. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Molinolo AA, Amornphimoltham P, Squarize
CH, Castilho RM, Patel V and Gutkind JS: Dysregulated molecular
networks in head and neck carcinogenesis. Oral Oncol. 45:324–334.
2009. View Article : Google Scholar :
|
|
50
|
Khan KH, Yap TA, Yan L and Cunningham D:
Targeting the PI3K-AKT-mTOR signaling network in cancer. Chin J
Cancer. 32:253–265. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Prodromidis G, Nikitakis NG and Sklavounou
A: Immunohistochemical Analysis of the Activation Status of the
Akt/ mTOR/pS6 Signaling Pathway in Oral Lichen Planus. Int J Dent.
2013:7434562013. View Article : Google Scholar
|
